Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis

BMC Endocrine Disorders

Marcia F. T. Rupnow²  Henry J. Henk¹  Wing Chow²  Erin K. Buysman¹ 

[1] Health Economics & Outcomes Research, Optum, 11000 Optum Circle, Eden Prairie 55344, MN, USA;Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, 1000 Route 202 - Room 3263, Raritan 08869, NJ, USA

关键词: A1C levels;    Treatment patterns;    Real-world;    Type 2 diabetes mellitus;    Canagliflozin;   

Others  :  1230182
DOI  :  10.1186/s12902-015-0064-8

 received in 2015-07-17, accepted in 2015-10-23,  发布年份 2015

【 摘 要 】

Background

Canagliflozin, an oral agent that inhibits sodium glucose co-transporter 2, improves glycemic control, body weight, and blood pressure and is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). This study extends the scope of previous analyses by evaluating outcomes associated with the use of canagliflozin over a 6-month period in a real-world setting.

Methods

This retrospective cohort study used data obtained from a large health plan database for patients (≥18 years) with a diagnosis of T2DM who filled at least one canagliflozin prescription between April 1, 2013 and October 30, 2013 (first 7 months canagliflozin was commercially available in the USA) and were continuously enrolled in the health plan for 6 months prior to (baseline) and 6 months following the first canagliflozin prescription claim (follow-up). Changes in glycemic control were evaluated, along with characteristics of enrolled patients and changes in treatment patterns.

Results

4017 patients (mean age 56 years, 43 % female) met the study inclusion criteria. Of these, at the time of first canagliflozin claim, 21 % used canagliflozin concomitantly with three or more other antihyperglycemic agents (AHAs), 29 % with two other AHAs, 30 % with one other AHA, and 20 % without other AHAs. During follow-up, patients received 3.4 (average) canagliflozin prescription fills and a mean of 148 total days of supply; median adherence (interquartile range [IQR]) was 86 % (66–98 %) for patients with ≥2 fills. Among patients with available glycated hemoglobin (A1C) measurements at baseline and follow-up (n = 826, baseline A1C 8.59 %), mean A1C reduction was 0.81 % (P < 0.001). Mean A1C reduction during the follow-up period was greatest in patients with the highest baseline A1C levels. Of the patients who used canagliflozin concomitantly with other AHAs, 20 % were observed to discontinue one or more other AHAs during follow-up. The most commonly discontinued baseline AHAs were: glucagon-like peptide-1 receptor agonists (16 %), dipeptidyl peptidase-4 inhibitors (15 %), insulin (13 %), sulfonylureas (13 %), and metformin (11 %).

Conclusions

This real-world study on canagliflozin use in a range of patients with T2DM demonstrated significant improvements in mean A1C from baseline following the first canagliflozin prescription. In patients concomitantly using one or more additional AHAs at baseline, there appears to be a trend toward lower other AHA use after canagliflozin initiation.

【 授权许可】

   
2015 Buysman et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]National Diabetes Statistics Report. 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed 9 March 2015.
• [2]Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al.. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38:140-149.
• [3]American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl1):S4.
• [4]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
• [5]Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al.. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-412.
• [6]Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-1589.
• [7]Agency for Healthcare Research and Quality. Clinical practice guideline for type 2 diabetes. 2013. http://www.guideline.gov/content.aspx?id=36628. Accessed 10 March 2015.
• [8]Casagrande SS, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013; 36:2271.
• [9]Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al.. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364-1379.
• [10]NCQA. Proposed Changes to Existing Measure for HEDIS®1 2015: Comprehensive Diabetes Care (CDC). http://www.ncqa.org/Portals/0/HomePage/CDC.pdf. Accessed 10 March 2015.
• [11]Medicare Shared Savings Program. Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 and 2015 Reporting Years. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/MSSP-QM-Benchmarks.pdf. Accessed 10 March 2015.
• [12]Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N et al.. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013; 36:2154-2161.
• [13]Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al.. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015; 21:438-447.
• [14]Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS et al.. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015; 21:1-87.
• [15]Annemans L, Aristides M, Kubin M. Real life data: a growing need. ISPOR Connect. 2007; 13:8-12.
• [16]Saunders C, Byrne CD, Guthrie B, Lindsay RS, McKnight JA, Philip S et al.. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013; 30:300-308.
• [17]Buysman EK, Chow W, Henk HJ, Rupnow MF. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin. 2015; 31:137-143.
• [18]Pharmacy Quality Alliance. Proportion of Days Covered (PDC) as a preferred method of measuring medication adherence. http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf. Accessed May 10 2015.
• [19]Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ et al.. Diabetes complications severity index and risk of mortalitiy, hospitalization, and healthcare utilization. Am J Manag Care. 2008; 14:15-23.
• [20]Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted diabetes complications severity index in claims data. Am J Manag Care. 2012; 18:721-726.
• [21]Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm. 2006; 12:130-142.
• [22]Oglesby AK, Secnik K, Barron J, Al Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: a longitudinal analysis [abstract]. Value Health. 2005; 8:356.
• [23]Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C et al.. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15:372-382.
• [24]Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–92.
• [25]Wilding JPH, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F et al.. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013; 67:1267-1282.
• [26]Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA et al.. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015; 38(3):355-364.
• [27]Ruokoniemi P, Sund R, Arffman M, Helin-Salmivaara A, Huupponen R, Keskimäki I et al.. Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. BMJ Open. 2014; 4:e005402.
• [28]Pharmacy Quality Alliance. PQA Measures. http://pqaalliance.org/measures/default.asp. Accessed 10 March 2015.
• [29]Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality. J Am Pharm Assoc. 2014; 54:228-240.
• [30]Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002; 25:1015-1021.
• [31]Schoenthaler A, Cuffee YL. A systematic review of interventions to improve adherence to diabetes medications within the patient-practitioner interaction. J Clin Outcomes Manag. 2013; 20(11):494-506.
• [32]Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood). 2012; 31:1836-1846.
• [33]Zullig LL, Gellad WF, Moaddeb J, Crowley MJ, Shrank W, Granger BB et al.. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015; 9:139-149.
• [34]Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009; 121:94-107.
• [35]Grandy S, Fox KM, Hardy E. Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). Curr Ther Res Clin Exp. 2013; 75:77-82.
• [36]Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014; 126(3):7-15.
• [37]Nardolillo A, Kane MP, Busch RS, Watsky J, Hamilton RA. A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes. 2014; 7:25-30.